
Immunome, Inc.
NASDAQ:IMNM
8.84 (USD) • At close July 3, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Immunome, Inc. |
Symbool | IMNM |
Munteenheid | USD |
Prijs | 8.84 |
Beurswaarde | 769,188,732 |
Dividendpercentage | 0% |
52-weken bereik | 5.15 - 16.81 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Clay B. Siegall Ph.D. |
Website | https://immunome.com |
An error occurred while fetching data.
Over Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)